PBE vs. CNCR ETF Comparison

Comparison of PowerShares Dynamic Biotech & Genome (PBE) to Loncar Cancer Immunotherapy ETF (CNCR)
PBE

PowerShares Dynamic Biotech & Genome

PBE Description

The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

Grade (RS Rating)

Last Trade

$69.14

Average Daily Volume

6,628

Number of Holdings *

30

* may have additional holdings in another (foreign) market
CNCR

Loncar Cancer Immunotherapy ETF

CNCR Description ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.

Grade (RS Rating)

Last Trade

$14.74

Average Daily Volume

3,771

Number of Holdings *

67

* may have additional holdings in another (foreign) market
Performance
Period PBE CNCR
30 Days -0.97% 0.07%
60 Days -3.80% -2.25%
90 Days 0.98% 3.58%
12 Months 26.96% 45.65%
4 Overlapping Holdings
Symbol Grade Weight in PBE Weight in CNCR Overlap
BPMC C 2.62% 1.32% 1.32%
EXEL A 3.18% 1.39% 1.39%
REGN F 4.15% 1.1% 1.1%
XNCR A 3.55% 1.35% 1.35%
PBE Overweight 26 Positions Relative to CNCR
Symbol Grade Weight
ILMN A 5.78%
ALNY C 5.57%
UTHR A 5.35%
AMGN C 5.1%
BIIB F 4.77%
BMRN F 4.1%
NBIX C 4.0%
MNKD A 3.48%
PTGX B 3.18%
CPRX A 3.01%
VCYT A 2.93%
TGTX A 2.89%
INCY A 2.87%
NTRA B 2.85%
BCRX A 2.83%
TECH B 2.82%
COLL F 2.74%
RGEN D 2.72%
QGEN D 2.64%
ACAD F 2.62%
NVAX F 2.59%
OPK C 2.56%
MYGN F 2.34%
HALO B 2.32%
VCEL D 2.28%
CDNA D 2.1%
PBE Underweight 63 Positions Relative to CNCR
Symbol Grade Weight
BMEA D -1.91%
TYRA F -1.89%
ELVN B -1.75%
HCM C -1.74%
ACLX B -1.55%
REPL B -1.55%
MGNX C -1.55%
YMAB A -1.54%
AURA B -1.54%
AUTL D -1.51%
KPTI C -1.5%
RVMD A -1.47%
BMY A -1.43%
DAWN A -1.42%
TSVT D -1.42%
ARVN C -1.42%
MRUS C -1.41%
MRSN D -1.41%
JANX A -1.4%
RPTX C -1.39%
RCUS F -1.38%
IGMS B -1.37%
BCYC D -1.37%
SNDX F -1.37%
KYMR C -1.36%
IOVA B -1.35%
ALLO D -1.35%
GNLX C -1.32%
ACRV B -1.32%
IMCR F -1.31%
NRIX B -1.31%
ACET F -1.3%
CRBU D -1.28%
STRO D -1.28%
RXRX F -1.28%
PGEN F -1.27%
GERN C -1.26%
LYEL F -1.25%
CGEM F -1.24%
SDGR F -1.23%
RAPT D -1.23%
ERAS C -1.23%
MRK F -1.22%
ZNTL D -1.22%
BNTX B -1.21%
IPHA D -1.18%
GLUE A -1.17%
LEGN F -1.16%
GMAB F -1.15%
NUVL D -1.13%
FHTX C -1.11%
KURA F -1.1%
SWTX D -1.09%
IDYA F -1.08%
RLAY F -1.05%
FATE F -1.03%
IMRX D -1.02%
NUVB F -1.02%
ITOS F -0.99%
IMTX F -0.99%
VOR D -0.94%
SMMT C -0.92%
PRLD F -0.85%
Compare ETFs